全球全外EXOME定序市場規模、佔有率、趨勢和成長分析報告（2026-2034年）

全EXOME定序市場預計將從 2025 年的 22.1 億美元成長到 2034 年的 80.5 億美元，預計從 2026 年到 2034 年將以 15.47% 的複合年成長率成長。

受基因組研究進展和個人化醫療日益成長的需求推動，全球全EXOME序市場正快速成長。全EXOME序專注於分析導致多種遺傳疾病的基因的蛋白質轉錄區。這項技術已成為醫學研究、診斷和藥物研發的關鍵工具，並支持市場的穩定擴張。

主要的促進因素包括遺傳疾病盛行率的上升以及對精準診斷方法日益成長的需求。研究人員和醫療保健專業人員正在利用全外EXOME定序來識別致病突變並開發標靶治療。此外，定序成本的降低和生物資訊學工具的改進使得這項技術更容易被研究機構和臨床檢查室所採用。

隨著基因組醫學的進步，全EXOME子定序市場前景依然光明。隨著其在臨床診斷、癌症研究和罕見疾病調查等領域的應用日益廣泛，其應用範圍可望進一步擴大。與人工智慧和大規模基因組資料庫的整合將提高數據解讀的準確性。隨著精準醫療的普及，全EXOME序可望在醫學創新中發揮關鍵作用。

目錄

第1章：引言

第2章執行摘要

第3章 市場變數、趨勢與框架

• 市場譜系展望
• 滲透率和成長前景分析
• 價值鏈分析
• 法律規範
  • 標準與合規性
  • 監管影響分析
• 市場動態
  • 市場促進因素
  • 市場限制因素
  • 市場機遇
  • 市場挑戰
• 波特五力分析
• PESTLE分析

第4章：全球全外EXOME市場：依產品類型分類

• 市場分析、洞察與預測
• 裝置
• 消耗品
• 服務

第5章：全球全外EXOME市場：依合成方法分類

• 市場分析、洞察與預測
• 離子半導體定序
• 其他技術

第6章：全球全外EXOME市場：依應用領域分類

• 市場分析、洞察與預測
• 藥物發現與開發
• 臨床診斷
• 研究

第7章：全球全外EXOME定序市場：依適應症分類

• 市場分析、洞察與預測
• 癌症
• 罕見疾病和遺傳疾病
• 感染疾病
• 心血管疾病
• 神經系統疾病
• 其他

第8章：全球全外EXOME市場：依最終用戶分類

• 市場分析、洞察與預測
• 醫院和診所
• 診斷檢測實驗室
• 學術研究機構
• 生物製藥公司

第9章：全球全外EXOME定序市場：依地區分類

• 區域分析
• 北美市場分析、洞察與預測
  • 美國
  • 加拿大
  • 墨西哥
• 歐洲市場分析、洞察與預測
  • 英國
  • 法國
  • 德國
  • 義大利
  • 俄羅斯
  • 其他歐洲國家
• 亞太市場分析、洞察與預測
  • 印度
  • 日本
  • 韓國
  • 澳洲
  • 東南亞
  • 其他亞太國家
• 拉丁美洲市場分析、洞察與預測
  • 巴西
  • 阿根廷
  • 秘魯
  • 智利
  • 其他拉丁美洲國家
• 中東和非洲市場分析、洞察與預測
  • 沙烏地阿拉伯
  • UAE
  • 以色列
  • 南非
  • 其他中東和非洲國家

第10章 競爭格局

• 最新趨勢
• 公司分類
• 供應鏈和銷售管道合作夥伴（根據現有資訊）
• 市場佔有率和市場定位分析（基於現有資訊）
• 供應商情況（基於現有資訊）
• 策略規劃

第11章：公司簡介

• 主要公司的市佔率分析
• 公司簡介
  • Thermo Fisher Scientific Inc
  • Roche Diagnostics（F. Hoffmann La Roche Ltd.）
  • Illumina Inc
  • Eurofins Scientific SE
  • QIAGEN NV
  • BGI Genomics Co. Ltd
  • Novogene Co. Ltd
  • Pacific Biosciences Of California Inc
  • Agilent Technologies Inc
  • Genomatix GmbH
  • Myriad Genetics Inc
  • Bio Rad Laboratories Inc
  • Laboratory Corporation Of America Holdings
  • Oxford Nanopore Technologies Plc
  • Novogene Co. Ltd

The Whole Exome Sequencing Market size is expected to reach USD 8.05 Billion in 2034 from USD 2.21 Billion (2025) growing at a CAGR of 15.47% during 2026-2034.

The global whole exome sequencing market has grown rapidly due to advancements in genomic research and increasing interest in personalized medicine. Whole exome sequencing focuses on analyzing the protein-coding regions of genes, which are responsible for many genetic diseases. The technology has become an important tool in medical research, diagnostics, and drug discovery, supporting the market's steady expansion.

Key drivers include the rising prevalence of genetic disorders and increasing demand for precise diagnostic methods. Researchers and healthcare providers are using whole exome sequencing to identify disease-causing mutations and develop targeted therapies. Additionally, declining sequencing costs and improvements in bioinformatics tools have made the technology more accessible for research institutions and clinical laboratories.

The future outlook for the whole exome sequencing market remains promising as genomic medicine continues to advance. Growing adoption in clinical diagnostics, cancer research, and rare disease studies may expand its applications further. Integration with artificial intelligence and large genomic databases could enhance data interpretation. As precision medicine becomes more widely adopted, whole exome sequencing is expected to play a critical role in healthcare innovation.

MARKET SEGMENTATION

By Product Type

• Instruments
• Consumables
• Services
• Sequencing by Synthesis
• Ion Semiconductor Sequencing
• Other Technologies

By Application

• Drug Discovery & Development
• Clinical Diagnostics
• Research

By Indication

• Cancer
• Rare/Inherited Diseases
• Infectious Diseases
• Cardiovascular Diseases
• Neurological Disorders
• Others

By End User

• Hospitals & Clinics
• Diagnostics Laboratories
• Academic and Research Institutes
• Biopharmaceutical Companies

COMPANIES PROFILED

• Thermo Fisher Scientific Inc, Roche Diagnostics F Hoffmann La Roche Ltd, Illumina Inc, Eurofins Scientific SE, QIAGEN NV, BGI Genomics Co Ltd, Novogene Co Ltd, Pacific Biosciences of California Inc, Agilent Technologies Inc, Genomatix GmbH, Myriad Genetics Inc, Bio Rad Laboratories Inc, Laboratory Corporation of America Holdings, Oxford Nanopore Technologies plc, Novogene Co Ltd
• We can customise the report as per your requirements.

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL WHOLE EXOME SEQUENCING MARKET: BY PRODUCT TYPE 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Product Type
• 4.2. Instruments Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Consumables Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.4. Services Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL WHOLE EXOME SEQUENCING MARKET: BY SEQUENCING BY SYNTHESIS 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Sequencing By Synthesis
• 5.2. Ion Semiconductor Sequencing Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Other Technologies Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL WHOLE EXOME SEQUENCING MARKET: BY APPLICATION 2022-2034 (USD MN)

• 6.1. Market Analysis, Insights and Forecast Application
• 6.2. Drug Discovery & Development Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.3. Clinical Diagnostics Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.4. Research Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL WHOLE EXOME SEQUENCING MARKET: BY INDICATION 2022-2034 (USD MN)

• 7.1. Market Analysis, Insights and Forecast Indication
• 7.2. Cancer Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.3. Rare/Inherited Diseases Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.4. Infectious Diseases Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.5. Cardiovascular Diseases Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.6. Neurological Disorders Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.7. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 8. GLOBAL WHOLE EXOME SEQUENCING MARKET: BY END USER 2022-2034 (USD MN)

• 8.1. Market Analysis, Insights and Forecast End User
• 8.2. Hospitals & Clinics Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 8.3. Diagnostics Laboratories Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 8.4. Academic and Research Institutes Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 8.5. Biopharmaceutical Companies Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 9. GLOBAL WHOLE EXOME SEQUENCING MARKET: BY REGION 2022-2034 (USD MN)

• 9.1. Regional Outlook
• 9.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 9.2.1 By Product Type
  • 9.2.2 By Sequencing By Synthesis
  • 9.2.3 By Application
  • 9.2.4 By Indication
  • 9.2.5 By End User
  • 9.2.6 United States
  • 9.2.7 Canada
  • 9.2.8 Mexico
• 9.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 9.3.1 By Product Type
  • 9.3.2 By Sequencing By Synthesis
  • 9.3.3 By Application
  • 9.3.4 By Indication
  • 9.3.5 By End User
  • 9.3.6 United Kingdom
  • 9.3.7 France
  • 9.3.8 Germany
  • 9.3.9 Italy
  • 9.3.10 Russia
  • 9.3.11 Rest Of Europe
• 9.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 9.4.1 By Product Type
  • 9.4.2 By Sequencing By Synthesis
  • 9.4.3 By Application
  • 9.4.4 By Indication
  • 9.4.5 By End User
  • 9.4.6 India
  • 9.4.7 Japan
  • 9.4.8 South Korea
  • 9.4.9 Australia
  • 9.4.10 South East Asia
  • 9.4.11 Rest Of Asia Pacific
• 9.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 9.5.1 By Product Type
  • 9.5.2 By Sequencing By Synthesis
  • 9.5.3 By Application
  • 9.5.4 By Indication
  • 9.5.5 By End User
  • 9.5.6 Brazil
  • 9.5.7 Argentina
  • 9.5.8 Peru
  • 9.5.9 Chile
  • 9.5.10 Rest of Latin America
• 9.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 9.6.1 By Product Type
  • 9.6.2 By Sequencing By Synthesis
  • 9.6.3 By Application
  • 9.6.4 By Indication
  • 9.6.5 By End User
  • 9.6.6 Saudi Arabia
  • 9.6.7 UAE
  • 9.6.8 Israel
  • 9.6.9 South Africa
  • 9.6.10 Rest of the Middle East And Africa

Chapter 10. COMPETITIVE LANDSCAPE

• 10.1. Recent Developments
• 10.2. Company Categorization
• 10.3. Supply Chain & Channel Partners (based on availability)
• 10.4. Market Share & Positioning Analysis (based on availability)
• 10.5. Vendor Landscape (based on availability)
• 10.6. Strategy Mapping

Chapter 11. COMPANY PROFILES OF GLOBAL WHOLE EXOME SEQUENCING INDUSTRY

• 11.1. Top Companies Market Share Analysis
• 11.2. Company Profiles
  • 11.2.1 Thermo Fisher Scientific Inc
  • 11.2.2 Roche Diagnostics (F. Hoffmann La Roche Ltd.)
  • 11.2.3 Illumina Inc
  • 11.2.4 Eurofins Scientific SE
  • 11.2.5 QIAGEN N.V
  • 11.2.6 BGI Genomics Co. Ltd
  • 11.2.7 Novogene Co. Ltd
  • 11.2.8 Pacific Biosciences Of California Inc
  • 11.2.9 Agilent Technologies Inc
  • 11.2.10 Genomatix GmbH
  • 11.2.11 Myriad Genetics Inc
  • 11.2.12 Bio Rad Laboratories Inc
  • 11.2.13 Laboratory Corporation Of America Holdings
  • 11.2.14 Oxford Nanopore Technologies Plc
  • 11.2.15 Novogene Co. Ltd